acq	icn pharmaceuticals icn seeking acquisition icn pharmaceuticals inc mln dlrs cash and another billion dlrs credit intends use buy pharmaceutical company chairman milan panic company annual meeting acquisition place months company two billion dlrs for acquisition today panic adding investigating number companies company studied possibly acquired friendly basis panic intends seek board approval today repurchase mln icn common shares discussing possibility acquisition panic such purchase icn current marketing capability not sufficient support distribution company products icn expectations for market growth worldwide icn principal product ribavirin virazole drug marketed number countries and described broad based anti viral company applications include treatment types hepatitis herpes influenza childhood diseases and hemorrhagic fevers icn focus consirable investor attention recent months virazole undergone clinical trials treatment aids related diseases panic today not discuss drug regard aids food and drug administration completes review data submitted company investigation drug conducted house subcommittee continuing subcommittee and fda acknowledged conducting separate investigations determine whether not icn witheld data fda adverse reactions drug virazole approved for marketing aerosol form treatment for infection that strikes infants called respiratory syncytial virus InformationRetrieval.reuter